AXIM® Biotechnologies Receives Medical Device Manufacturing License
The original release is unavailable here.
AXIM Biotechnologies, Inc. on 6ix
Earlier from AXIM Biotechnologies
- EQS-News: VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
- VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
- EQS-News: AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
- AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
- AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
Later from AXIM Biotechnologies
- Axim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
- AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests
- AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea
- AXIM Biotechnologies Engages 624 Advisors, Owned and Managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
- AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
Follow AXIM Biotechnologies into a list and get an email when it puts out news.
Follow AXIM Biotechnologies